Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GDC-9545 AME and Bioavailability Study
NCT04680273Phase 1Completed
- Sponsor
- Genentech
- Start
- Jan 2021
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of giredestrant in breast cancer (3 arms), sponsored by Genentech. Primary endpoints: Mean Cumulative Amount of Total Radioactivity (CumAe) of [14C]-GDC-9545 Excreted in Urine, Feces, and Total, Mean Cumulative Amount of Total Radioactivity Expressed as a Percentage of the Radioactive Dose Administered (CumFe) and 5 more. Started Jan 2021; status: completed.
02
Drugs
giredestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04680273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04680273.